Transthyretin cardiac amyloidosis
Disease1 paper5 findings
- Humans1
Effects
1Mortality
no changein humans1
1 study
Mortality
no changein humans1
Transthyretin cardiac amyloidosis has no effect on mortality in humans (p=0.137).
Humanscardiology inpatients with LVH3.31 yearsn = 400
Prospective Systematic Screening for Transthyretin Amyloid Cardiomyopathy in Cardiology Inpatients With Left Ventricular Hypertrophy: the IMPACT Study · European heart journal. Cardiovascular Imaging · 15 Sep 2026
Associations
4Stroke
upin humans1OR 8.67
1 study
Stroke
upin humans1OR 8.67
Stroke raises the risk of transthyretin cardiac amyloidosis in humans (OR 8.67, 95% CI 2.65-28.34).
Humansmultivariable logistic regressionn = 400
Prospective Systematic Screening for Transthyretin Amyloid Cardiomyopathy in Cardiology Inpatients With Left Ventricular Hypertrophy: the IMPACT Study · European heart journal. Cardiovascular Imaging · 15 Sep 2026
Bilateral carpal tunnel syndrome
upin humans1OR 3.48
1 study
Bilateral carpal tunnel syndrome
upin humans1OR 3.48
Bilateral carpal tunnel syndrome raises the risk of transthyretin cardiac amyloidosis in humans (OR 3.48, 95% CI 1.09-11.14).
Humansmultivariable logistic regressionn = 400
Prospective Systematic Screening for Transthyretin Amyloid Cardiomyopathy in Cardiology Inpatients With Left Ventricular Hypertrophy: the IMPACT Study · European heart journal. Cardiovascular Imaging · 15 Sep 2026
Non-sinus rhythm
upin humans1OR 3.85
1 study
Non-sinus rhythm
upin humans1OR 3.85
Non-sinus rhythm raises the risk of transthyretin cardiac amyloidosis in humans (OR 3.85, 95% CI 1.30-11.11).
Humansmultivariable logistic regressionn = 400
Prospective Systematic Screening for Transthyretin Amyloid Cardiomyopathy in Cardiology Inpatients With Left Ventricular Hypertrophy: the IMPACT Study · European heart journal. Cardiovascular Imaging · 15 Sep 2026
Left ventricular hypertrophy
upin humans1
1 study
Left ventricular hypertrophy
upin humans1
Left ventricular hypertrophy is associated with transthyretin cardiac amyloidosis in humans (7.3% (29/400)).
Humanscardiology inpatients with LVHn = 400
Prospective Systematic Screening for Transthyretin Amyloid Cardiomyopathy in Cardiology Inpatients With Left Ventricular Hypertrophy: the IMPACT Study · European heart journal. Cardiovascular Imaging · 15 Sep 2026
Funding
National Heart, Lung, and Blood InstituteUS$877.2kNational Institute on AgingUS$688.6k3 grants since 2022
National Heart, Lung, and Blood InstituteUT Southwestern Medical CenterUS$692.7k2022–2027
Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac Amyloidosis
National Heart, Lung, and Blood InstituteBrigham and Women's HospitalUS$184.5k2023–2028
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
National Institute on AgingColumbia University Health SciencesUS$688.6k2023–2028